Formulated by physicians from
Harvard, Cornell, MIT and Bastyr
Strong Bones. Guaranteed
You will see your bone density stabilize or improve in six months, but more importantly, we guarantee you’ll have strong bones. Therefore, if you break a bone we’ll refund your money for all your purchases since your previous bone scan.
Free eBook: Naturally Grow Stronger Bones and Reduce Fracture Risk
Which Osteo-K is Right for You?
How much calcium has your doctor recommended?
If less was recommended, or you believe that less calcium as a dietary supplement is better, then Osteo-K Minis is what you’ll want.
Do you eat dairy?
Do you have difficulty swallowing larger capsules?
However, if you feel less calcium is enough for you, and you can swallow the smaller capsules in Osteo-K Minis, then Osteo-K Minis is the product for you.
How many capsules each day can you regularly take?
If you want fewer capsules to take each day, while still getting the same, powerful bone-building benefits as in the original Osteo-K formula, then Osteo-K Minis is for you. But if you don’t mind taking more capsules (6 per day in Osteo-K versus 4 per day in Osteo-K Minis), and you like the idea of getting more calcium in your dietary supplement, then the original Osteo-K formula is the right choice.
MK4 Bone Health Research
The benefits of MK4 for bone health have been studied for more than 30 years and published in dozens of medical journals. There are over 25 clinical trials with more than 7,000 people. The research consistently shows that MK4 improves bone health laboratory markers, supports healthy bone structure and maintains strong bones as indicated by significantly fewer fractures.
Strong Bones. Active Life.
MK4 vs MK7 for Bone Health
There are two forms of vitamin K2 commercially available in dietary supplements: MK4 and MK7. While they’re both naturally found in food, your body can create its own MK4. This is not the case for MK7. We can’t make MK7, which is instead only created by bacterial fermentation. Natural MK4 used in dietary supplements is produced from a plant starting material.
MK7 has a longer half-life than MK4 and both can promote healthy bone laboratory markers and bone density. MK7, however, has never been shown in clinical trials to reduce fractures. Only MK4 has demonstrated the ability to reduce bone fractures in clinical trials.
However, only MK4 has demonstrated the ability to decrease fractures, the most relevant end point in randomized, controlled clinical trials. Additionally, people with an allergy to soy can react to MK7, since it is produced from soy fermentation. People with celiac disease and gluten intolerance frequently have allergies to other foods, such as soy. MK4 is hypoallergenic.
Why Osteo-K Shatters the Competition
*MK4 is the most researched form of vitamin K2 for bone health. It’s health benefits have been studied for more than thirty years. More than 25 clinical trials with over 7000 volunteers indicate that MK4 (45 mg/day) supports healthy bone density and maintains strong bones as indicated by more than 70% fewer fractures. Calcium and vitamin D have been shown to reduce fractures by 18%. MK7 has not been shown to reduce fractures as a primary endpoint in clinical trials. In a clinical trial of vitamin K1 as a dietary supplement, this nutrient did not maintain healthy bone density.
†Oxide minerals. Magnesium oxide is inexpensive and commonly found in vitamin and mineral formulas. People absorb only about 4% of the magnesium as magnesium oxide. This means that 96% of what you put in your mouth is just passing right through you and being eliminated in your stool. In fact, magnesium oxide is so poorly absorbed that it’s used in higher amounts as a laxative.
References: Cheung AM, Tile L, Lee Y, et al. 2008;5(10):e196. Cockayne S, Adamson J, Lanham-New S, et. al. 2006;166(12):1256-1261. Huang ZB,Wan SL, Lu YJ, et. al. 2015;26(3):1175-1186. Firoz M, Graber M. 2001;14(4):257‐262. Iwamoto J, Takeda T, Ichimura S.2001;6(6):487-492. Larsen ER, Mosekilde L, et. al. 2004;19(3):370- 378. Lindberg JS, Zobitz MM, Poindexter JR et al. 1990;9(1):48‐55. Shiraki M, Shiraki Y, et. al. 2000;15(3):515-522.
More Osteo-K Results
Osteo-K Frequently Asked Questions
General Osteo-K Questions
Yes, plus other important nutrients for bone health. Each six capsules of Osteo-K contain 45 mg of MK4, a form of vitamin K2, 1000 mg calcium (citrate) and 2000 units Vitamin D3.
Q: What is the source of MK4 in your products?
NBI’s MK4 is derived from Orange Jasmine (Murraya paniculata), leaf geraniol extract.
Q: Who created Osteo-K?
Osteo-K, a bone support dietary supplement, was created by physicians from Harvard, Cornell, MIT and Bastyr. After years of Dr. Steve Pieczenik’s wife taking Fosamax without any benefit, and with painful side effects, he and his partner, Dr. John Neustadt began researching natural ways women and men can promote their bone health.
Q: How is Osteo-K different from other bone support formulas?
Osteo-K is the only osteoporosis supplement that contains the amount (45 mg) and form of vitamin K (MK4) plus calcium and vitamin D shown in clinical trials to prevent fractures.
Q: Is Osteo-K gluten free?
Yes. All of our NBI dietary supplements are completely gluten free.
Q: Are the Osteo-K capsules vegetarian?
Yes. All our capsules are 100% vegetarian cellulose capsules.
Q: Why doesn’t Osteo-K contain strontium?
For several reasons. First, clinical trials show that MK4 decreases fractures better than strontium–81% for MK4 versus 44% for strontium. Second, strontium decreases calcium absorption, and calcium is an important nutrient. Third the form of strontium used in all the clinical trials is strontium ranelate. Currently strontium ranelate is only available in Europe. Strontium in the US is available as strontium citrate, which has never been studied and shown to decrease fractures. Finally, strontium interferes with bone density scans and provides false results. The question of strontium and osteoporosis is a good one, but the research at this time supports MK4 over strontium.
Who should take Osteo-K?
If you are concerned about your bone health, and are not taking Coumadin (warfarin), you should take Osteo-K.
Q: Can everyone take Osteo-K?
No. People taking warfarin (Coumadin) cannot take Osteo-K because the vitamin K in the dietary supplement will interfere with the warfarin.
Osteo-K, Calcium and Your Other Supplements
Q: Does Osteo-K interact with any other dietary supplements?
No. However, if you are taking different dietary supplements that also contain vitamin D and minerals, there is always a risk of taking too much vitamin D and too many minerals at the same time. Taking too many minerals can cause a watery diarrhea, technically called osmotic diarrhea. Simply taking Osteo-K away from other dietary supplements can correct this situation. If taking more than 100 mcg (4000 IU) vitamin D daily. Vitamin D blood level monitoring is recommended.
Q: Does Osteo-K replace my calcium supplement?
Yes. Because Osteo-K combines three of the most important micronutrients needfor bone health into one formd eula it’s the only dietary supplement you need for bone health. You don’t need to buy extra calcium unless advised to do so by your healthcare provider.
Q: Do I need to take extra vitamin D if I’m taking Osteo-K?
Only if your doctor has prescribed higher amounts of vitamin D than what is in Osteo-K. The total daily recommended amount (six capsules total divided into two servings) of Osteo-K contains 2,000 units of vitamin D3.
Osteo-K and Drug Interactions
No. MK4 does not interact with heparin.
Q: If I’m taking aspirin, can I still take Osteo-K?
Yes. None of the ingredients in Osteo-K, including MK4, interfere with the effects of aspirin.
Q: If I’m taking warfarin (Coumadin), can I still take Osteo-K?
No. Vitamin K, which is in Osteo-K, will interfere with warfarin (Coumadin). Warfarin works to prevent blood clots by blocking how the body uses vitamin K to form blood clots. Taking vitamin K while taking warfarin overrides this mechanism and makes warfarin less effective. People taking warfarin absolutely cannot take Osteo-K.
Q: Can I take Osteo-K with my osteoporosis medication?
Yes. The ingredients in Osteo-K are safe to take with osteoporosis medications.
MK4, Healthy Bones and Bone Strength
Yes. Osteo-K contains the amount of MK4 used in clinical trials, plus calcium and vitamin D3.
Q: What is MK4 and how does it work?
MK4 is a form of vitamin K2 and the principal ingredient in Osteo-K. MK4 works by activating genes involved in promoting bone health through the formation of bone collagen and bone mineralization. These genes include growth differentiation factor 15 (GDF15), Stanniocalcin, Tenascin-c and bone morphogenic protein-2 (BMP-2). Only MK4 has been shown to activate all these genes.
Q: Has MK4 been shown to maintain bone strength?
Yes. In clinical trials MK4 (45 mg/day when taken in divided doses) has been shown to be an important nutrient for bone health. More than 25 clinicals trials with over 7000 volunteers conclude that MK4 (45 mg/day) maintains strong bones.
Q: Is MK4 a drug?
No. MK4 is a naturally occuring form of vitamin K2 and is a dietary supplement. It has not been approved by the FDA to prevent, treat or cure any disease.
Q: Is 45 mg of MK4 safe?
Vitamin K is important for healthy blood clotting. However, taking extra vitamin K does not increase your risk. Studies have shown that taking in excess of even 135 mg/day of MK4 does not increase blood clot risk. That’s because once the body has enough vitamin K for normal clotting, it cannot use more. NOTE: If you are at increased risk of blood clots and are taking warfarin (Coumadin), MK-4 counteracts the intended action of this medication.
Q: How does MK4 compare with MK7?
MK4 and MK7 are forms of vitamin K2. The health benefits of MK4 have been researched for more than thirty years and it’s the most-studied form of vitamin K2 for bone health. Only MK4 has been shown to maintain strong bones; support brain, liver and immune health; and promote healthy bone marrow and blood cell production.
Q: How does MK4 compare with strontium?
MK4 clinical trials compared to strontium clinical trials showed that MK4 had a superior ability to support healthy bones.
Q: Will I maintain strong bones if I take MK4?
Studies show that MK4 can help support strong bones in clinical trials that compared people taking 45 mg per day of MK4 to people not taking MK4.
Vitamin D does a whole lot more than support healthy bones. Vitamin D supports brain health, muscle size and strength, heart health, mood, pancreas health and insulin balance. This blog discusses six surprising benefits of vitamin D and six more reasons to make sure you get enough of this powerful nutrient.
MK4 is a specific form of vitamin K2. And while MK4 is best known for bone health, it’s an important nutrient used throughout your body. Among all the forms of vitamin K2, only MK4 has been shown to maintain strong bones; support brain, liver, and immune health; and promote healthy bone marrow and blood cell production.
Collagen destruction is your visible sign of aging. As we age, our skin gradually loses elasticity and fullness. More wrinkles start to appear when you look in the mirror, skin becomes drier and thinner. Joints may start to creak, crackle, twinge and ache. Destructions of collagen is an underlying cause of all of this. And if you look in the mirror and see more wrinkles, you should assume that what’s happening on the outside is also happening on the inside. The amount of collagen in the skin declines in post-menopausal women at the same time as bone mineral density declines. Learn how menopause destroys collagen and what you can do about it.
Studies on MK4 for Maintaining Strong Bones
- Adams J, Pepping J. 2005;62(15):1574-1581.
- Anderson PH, Sawyer RK, May BK, et. al. 2007;103(3-5):592-595.
- Asakura H, Myou S, Ontachi Y, et al. 2001;12(12):996-1000.
- Booth SL, Tucker KL, Chen H, et al. 2000;71(5):1201-1208.
- Carrié I, Portoukalian J, Vicaretti R, et. al. 2004;134(1):167-172.
- Cockayne S, Adamson J, Lanham-New S, et. al. 2006;166(12):1256-1261.
- Davidson RT, Foley AL, Engelke JA, Suttie JW. 1998;128(2):220-223.
- Dewar DH, Ciclitira PJ. 2005;128(4, Supplement 1):S19-S24.
- Fairfield KM, Fletcher RH. 2002;287(23):3116-3126.
- Ferland G. 2013;39(8):849-855.
- Fujishiro A, Iwasa M, Fujii S, et al. 2020;112(3):316-330.
- Gallagher JC, Rapuri P, Smith L. 2007;103(3-5):610-613.
- Grant AM, Avenell A, Campbell MK, et al. Lancet. 2005;365(9471):1621-1628.
- Green PH, Jabri B. 2003;362(9381):383-391.
- Green PH. 2005;128(4, Supplement 1):S74-S78.
- Hara K, Kobayashi M, Akiyama Y. 2002;31(5):575-581.
- Hernandez L, Green PH. 2006;8(5):383-389.
- Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, Fan SW. 2015;26(3):1175-1186.
- Ichikawa T, Horie-Inoue K, Ikeda K, et. al. 2006;281(25):16927-16934.
- Ichikawa T, Horie-Inoue K, Ikeda K, et. al. 2007;39(4):239-247.
- Ide Y, Zhang H, Hamajima H, et al. 2009;22(3):599-604.
- Igarashi M, Yogiashi Y, Mihara M, et. al. 2007;27(22):7947-7954.
- Iketani T, Kiriike N, B. Stein M, et al. 2003;117(3):259-269.
- Inoue T, Sugiyama T, Matsubara T, et al. 2001;48:11-18.
- Iwamoto I, Kosha S, Noguchi S, et al. 1999;31:161-164.
- Iwamoto J, Takeda T, Ichimura S. 2000;5(6):546-551.
- Iwamoto J, Takeda T, Ichimura S. 2001;6(6):487-492.
- Iwamoto J, Takeda T, Ichimura S. 2003;44:751-756.
- Iwamoto J, Takeda T, Sato Y, Yeh JK. 2007;25(1):46-53.
- Jesudason D, Bone. 2002;31(5):626-630.
- Kaneki M, Hosoi T, Ouchi Y, et. el. 2006;22(7-8):845-852.
- Kemppainen T, Kroger H, Janatuinen E, et al. 1999;24(3):249-255.
- Koshihara Y, Hoshi K, Okawara R, et. al. 2003;176(3):339-348.
- Larsen ER, Mosekilde L, Foldspang A. 2004;19(3):370-378.
- Masterjohn C. 2007;68(5):1026-1034.
- Miyake N, Hoshi K, Sano Y, Kikuchi K, et. al. 2001;12(8):680-687.
- Naim A, Pan Q, Baig MS. 2017;7(4):367-372.
- Nishiguchi S, Shimoi S, Kurooka H, et al. 2001;35:543-545.
- Ozaki I, Zhang H, Mizuta T, et al. 2007;13(7):2236-2245.
- Pizzorno L, Pizzorno J. 2008;7(2):24-30.
- Plaza SM, Lamson DW. 2005;10(1):24-35.
- Purwosunu Y, Rachman IA, Reksoprodjo S, et. al. 2006;32(2):230-234.
- Richard J. Farrell CPK. 96(12):3237-3246.
- Rodrigo L. 2006;12(41):6585-6593.
- Ronden JE, Drittij-Reijnders M-J, Vermeer C, et. al. 1998;1379(1):69-75.
- Ronden JE, Groenen-van Dooren MMCL, et. al. 1997;132(1):61-67.
- Sasaki N, Kusano E, Takahashi H, et al. 2005;23(1):41-47.
- Sato Y, Honda Y, Kaji M, et al. 2002;31:114-118.
- Sato Y, Honda Y, Kuno H, et. al. 1998;23(3):291-296.
- Schurgers LJ, Dissel PE, Spronk HM, et al. 2001;90 Suppl 3:57-63.
- Shearer MJ, Newman P. 2008;100(4):530-547.
- Shearer MJ, Newman P. 2014;55(3):345-362.
- Shiomi S, Nishiguchi S, Kubo S, et al. 2002;97(4):978-981.
- Shiraki M, Shiraki Y, Aoki C, et. al. 2000;15(3):515-522.
- Somekawa Y, Chigughi M, Harada M, Ishibashi T. 1999;84:2700-2704.
- Spronk HMH, Soute BAM, Schurgers LJ, et. el. 2003;40(6):531-537.
- Stenson WF, Newberry R, Lorenz R, et. al. 2005;165(4):393-399.
- Sugiyama T, Tanaka H, Kawai S. Clinical vignette. 1999;14:1466-1467.
- Tabb MM, Sun A, Zhou C, et al.2003;278(45):43919-43927.
- Ushiroyama T, Ikeda A, Ueki M. 2002;41(3):211-221.
- Vermeer C, Jie KS, Knapen MH. 1995;15:1-22
- Wallin R, Schurgers L, Wajih N. 2008;122(3):411-417.
- Wu WJ, Kim MS, Ahn BY. 2015;6(10):3351-3358.
- Yamaguchi M, Weitzmann MN. 2011;27(1):3-14.
- Yonemura K, Fukasawa H, Fujigaki Y, Hishida A. 2004;43:53-60.
- Yonemura K, Kimura M, Miyaji T, Hishida A. 2000;66:123-128.